Share Email Print
cover

Proceedings Paper

Plasmonic nanobubbles for target cell-specific gene and drug delivery and multifunctional processing of heterogeneous cell systems
Author(s): Ekaterina Y. Lukianova-Hleb; Leslie E. Huye; Malcolm K. Brenner; Dmitri O. Lapotko
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Cell and gene cancer therapies require ex vivo cell processing of human grafts. Such processing requires at least three steps – cell enrichment, cell separation (destruction), and gene transfer – each of which requires the use of a separate technology. While these technologies may be satisfactory for research use, they are of limited usefulness in the clinical treatment setting because they have a low processing rate, as well as a low transfection and separation efficacy and specificity in heterogeneous human grafts. Most problematic, because current technologies are administered in multiple steps – rather than in a single, multifunctional, and simultaneous procedure – they lengthen treatment process and introduce an unnecessary level of complexity, labor, and resources into clinical treatment; all these limitations result in high losses of valuable cells. We report a universal, high-throughput, and multifunctional technology that simultaneously (1) inject free external cargo in target cells, (2) destroys unwanted cells, and (3) preserve valuable non-target cells in heterogeneous grafts. Each of these functions has single target cell specificity in heterogeneous cell system, processing rate > 45 mln cell/min, injection efficacy 90% under 96% viability of the injected cells, target cell destruction efficacy > 99%, viability of not-target cells >99% The developed technology employs novel cellular agents, called plasmonic nanobubbles (PNBs). PNBs are not particles, but transient, intracellular events, a vapor nanobubbles that expand and collapse in mere nanoseconds under optical excitation of gold nanoparticles with short picosecond laser pulses. PNBs of different, cell-specific, size (1) inject free external cargo with small PNBs, (2) Destroy other target cells mechanically with large PNBs and (3) Preserve non-target cells. The multi-functionality, precision, and high throughput of all-in-one PNB technology will tremendously impact cell and gene therapies and other clinical applications that depend on ex vivo processing of heterogeneous cell systems.

Paper Details

Date Published: 7 March 2014
PDF: 7 pages
Proc. SPIE 8972, Frontiers in Ultrafast Optics: Biomedical, Scientific, and Industrial Applications XIV, 897206 (7 March 2014); doi: 10.1117/12.2039851
Show Author Affiliations
Ekaterina Y. Lukianova-Hleb, Rice Univ. (United States)
Leslie E. Huye, Baylor College of Medicine (United States)
Malcolm K. Brenner, Baylor College of Medicine (United States)
Dmitri O. Lapotko, Rice Univ. (United States)


Published in SPIE Proceedings Vol. 8972:
Frontiers in Ultrafast Optics: Biomedical, Scientific, and Industrial Applications XIV
Alexander Heisterkamp; Peter R. Herman; Michel Meunier; Stefan Nolte, Editor(s)

© SPIE. Terms of Use
Back to Top